Variation of HLA-DPB1 Gene in Hepatitis B Infection

Guo-Jin Ou
Institution of Blood Transfusion, CAMS&PUMC

Xiao Liu
Deyang people's hospital, Deyang, Sichuan, China

Haixia Xu
Clinical blood transfusion research center, Institute of Blood Transfusion, CAMS & PUMC, Chengdu, Sichuan, China. Key laboratory of transfusion adverse reactions, CAMS & PUMC, Chengdu, Sichuan, China

Xin Ji
Clinical blood transfusion research center, Institute of Blood Transfusion, CAMS & PUMC, Chengdu, Sichuan, China. Key laboratory of transfusion adverse reactions, CAMS & PUMC, Chengdu, Sichuan, China

Xiaojuan Liu (✉ Liuxiaojuantg@163.com)
Department of laboratory medicine, West China second university hospital, Chengdu, Sichuan, China. Key laboratory of birth defects and related diseases of women and children (Sichuan University), Ministry of Education

Jue Wang
Clinical blood transfusion research center, Institute of Blood Transfusion, CAMS & PUMC, Chengdu, Sichuan, China. Key laboratory of transfusion adverse reactions, CAMS & PUMC, Chengdu, Sichuan, China

Research

Keywords: HLA-DPB1 gene, Expression, HBV susceptible, HBV spontaneous clearance

DOI: https://doi.org/10.21203/rs.3.rs-52937/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Hepatitis B virus (HBV) affects approximately 68 million people in China. 10-15% of adult infected with HBV will develop to chronic HBV, liver cirrhosis (LC), liver failure and hepatocellular carcinoma (HCC). The human leukocyte antigen HLA-DPB1 gene polymorphism and expression were identified to be associated with HBV susceptible and spontaneous clearance. We evaluated the role of HLA-DPB1 gene polymorphism in HBV infection.

**Methods:** In this study, HLA-DPB1, rs9277535 polymorphisms were investigated in 259 HBV infection patients (CHB) and 442 healthy controls (HC) by using a sequence based typing. The mRNA of HLA-DPB1 were measured by real-time polymerase chain reaction (RT-PCR).

**Results:** The results shown that DPB1 gene, rs9277535 were all associated with HBV infection in the Sichuan Han population. Rs9277535A, DPB1*04:02 play a protected role in HBV infection, Rs9277535G, DPB1*05:01 prone to susceptible to HBV infection. Rs9277535GG have significantly higher HLA-DPB1 mRNA expression in HBV group compared that in HC group. DPB1*05:01 and DPB1*21:01 have a significantly lower HLA-DPB1 mRNA expression in HBV infection group compared than HC group. The meta-analysis revealed that HLA-DPB1*02:01, DPB1*02:02, DPB1*04:01 and DPB1*04:02 protected against HBV infection, while DPB1*05:01, DPB1*09:01, and DPB1*13:01 were risk factors for HBV infection susceptibility. DPB1*02:01 and DPB1*04:01 were prone to HBV spontaneous clearance, while DPB1*05:01 and DPB1*13:01 were associated with chronic HBV infection.

**Conclusions:**

DPB1 alleles and rs9277535 have a major effect on the risk of HBV infection, HBV infection associated with lower HLA-DPB1 expression. DPB1 alleles have important role in HBV susceptible and spontaneous clearance.

**Background**

As a relatively high prevalence HBV in China, the seropositive of HBsAg was estimated about 5.49%\(^1\) in 2015, that means approximately 93 million people infected by HBV, and 10–20% of adult HBV infections will progress to chronic HBV infection, alone or in combination with liver cirrhosis (LC) and/or hepatocellular carcinoma (HCC)\(^2\), lead to a heavy public health burden of HBV related liver disease in China\(^3\).

Multiple factors attributed the risk of chronic HBV infection, such as age, gender, BMI, ethnicity, viral mutation and genotypes, host genetic variations and related host immune responses and so on. A genome-wide association study\(^4\) (GWAS) in Japanese and other Asian populations found a significant association of chronic hepatitis B with several polymorphisms of the HLA loci including HLA-DPB1 and associated SNP rs9277535A/G. Subsequently, they revealed risk alleles DPB1*0501 and DPB1*0301, and protective alleles DPB1*0402 and DPB1*0401, respectively. Many researches\(^5\)–\(^11\) verified these results in
different ethnic genetic populations, they revealed that HLA-DPB1 and rs9277535A/G not only related with susceptible HBV infection but also affect the results of HBV infection, to be spontaneous clearances or to be chronic HBV infections.

Recent years, researchers\cite{12} found that risk alleles of HLA-DP decrease liver mRNA expression of HLA-DP in HBV patients, suggesting that expression of HLA-DP genes is important in control of HBV in non-Hispanic European. Thomas and his colleagues found\cite{13} that the rs9277534A/G variant distinguishes the most protective HLA-DPB1 allele (DPB1*04:01) from the most susceptible (DPB1*01:01) after HBV infection, they also confers rs9277534GG have significantly higher levels of HLA-DPB1 surface protein and transcript level expression in healthy donors compared than rs9277534AA genotype, rs9277534A/G can be an HLA-DPB1 expression marker\cite{14}, Decreased expression of DPB1 mRNA are associated with HBV reactivation in patients treated with immunomodulatory agents\cite{15}, and increased HCV-related liver disease and correlated with HCV related disease progression\cite{16}. These results suggesting that differences HLA-DPB1 alleles and DPB1 expression may influence the risk of persistent HBV infection.

The latest research found\cite{17} that subset of HLA-DP molecules, such as HLA-DP401, which interact with NKp44 trigger functional NK cell responses. This interaction between DP alleles and NKp44 implicates HLA class II as a component of innate immune response, much like HLA-C and KIR molecular. It may provide a potential mechanism\cite{18} for the relationship between HLA-DP alleles and disease outcomes, including HBV infection. It’s speculates that during acute HBV infection, NKp44 interacts with HLA-DP401 allele expressed on the surface of infected hepatocytes, IFN-γ was secreted both by Th1 and NK cells which contributing to lysis of HBV infected cells. In HBV infected individuals carrying HLA-DP301, NKp44 is unable to bind to HLA-DP301 molecules, resulting in inefficient lysis of infected hepatocytes by NK cells and lead to higher risk of chronic HBV infection.

The distribution of HLA-DPB1 molecules in Chinese populations were similar to those in Asian populations, HLA-DPB1 expression in HBV infection in Asian population haven’t reported yet. In this research, we typed HLA-DPB1 and associated rs9277535A/G in a population-based case control study in Chinese Han population, including 259 HBV cases and 441 controls from Sichuan province, also identified the different HLA-DPB1 expression in different alleles of these two groups.

**Methods**

**Samples**

The samples involved in this study were from physical examination center of Deyang people hospital, Sichuan province, China. A total of 499 participants, including 259 chronic HBV carriers (CHB) and 441 healthy controls (HC).

The HBV subjects were determined based on the serological results of Hepatitis B surface antigen (HBsAg), antibody against Hepatitis B surface antibody (HBsAb), Hepatitis Be antigen (HBeAg), antibody against Hepatitis Be (HBeAb) and total antibody against HBV core antigen (HBcAb) tests. Volunteers and
patients with seropositive for HBsAg combine with seropositive for HBeAg and HBcAb or HBeAb and HBcAb and positive of HBsAg at least lasting 6 months were considered to be CHB carriers, the HC who were seronegative for both HBsAg and HBeAg. All blood samples were negative for Hepatitis C virus (HCV) and Human immunodeficiency virus (HIV).

Subjects who were seropositive for HBsAg, had normal serum alanine aminotransferase (ALT) levels (lower than 35 U/L), had no obvious clinical symptoms were considered to be asymptomatic carriers and had not use any antiretroviral drugs. Each subject gave his/her written informed consent before enrolment.

**rs9277535 and HLA-DPB1 genotyping**

The peripheral blood of all samples and DNA extraction were performed as consistent with previous reported [19, 20]. Genotyping was performed using sequence based typing (PCR-SBT). Amplification primers were following: rs9277535: Forward was 5’- TAACTGTGTGTGGTCTGCTG, reward was 5’-CTCGCTGTGGTGAAGAACAGG, for amplify HLA-DPB1 exon 2, forward primer was 5’-CTGCGTGGTGAAGAACAGG, 5’- CCTGACAAGCTCCAGATGGG, reward primer was 5’-TTCTTTATGCTGTGGCTCCT. For each PCR mix (total volume, 10uL) contained 1ul DNA and 5uM primers and 5uL GoTaq Green Master Mix (Promega, Madison, USA). The DPB1 ambiguities were resolved by group-specific sequencing primers (GSSPs) sequencing, each primer was referenced by EBI-IMGT database. primers were shown in Table 1. Thermal cycling conditions were as followed: 96°C for 3 min, 30 cycles at 95°C for 20s, 62°C for 15s, 72°C for 1min, and 72°C for 5 min. The PCR products were analyzed by an ABI 3730 DNA Sequencer (Applied Biosystem, Foster City, CA).

| Primers       | Directions | Sequences                            | Positions |
|---------------|------------|--------------------------------------|-----------|
| DPB1-Z38R1    | Reward     | CGA CGT CCC AGT GCC GGA              | 341       |
| DPB1-Z38R2    | Reward     | GAG CCG CGA CGT CCC AGT GCC G        | 346       |
| DPB1-Z39F1    | Forward    | CCC CGC AGA GAA TTA CC               | 109       |
| DPB1-Z39F2    | Forward    | GC AGA GAA TTA CCT TTT              | 113       |
| DPB1-Z62R     | Reward     | AGC ATC AAC ACA GAC GTG              | 315       |
| DPB1-Z64R     | Reward     | ACA AGG TCA TGA GGC GTC             | 251       |
| DPB1-Z65R     | Reward     | CCG ACA AGG TCA TGA GGC             | 294       |

Group-specific sequencing primers used to resolve alternative genotypes, the primers based on ambiguous genotypes obtained
HLA-DPB1 mRNA level measurement

RNA were prepared from cell suspensions of each sample freshly isolated peripheral blood mononuclear cell (PBMC) using a TRIzol method (Invitrogen), the RNA extraction and cDNA preparation were also consistent with previous reported \[19, 20\].

The expression of HLA-DPB1 were quantified by SYBR green quantitative PCR (qPCR) using the threshold cycle (CT) method in CFX96 Touch PCR machine (Bio-Rad) with primers Forward: 5’-GTGCATTGCAGAAGGTCAGA-3’; Reward: 5’-CTGGTGATAGGCCATCAGGT-3’. Each PCR were triplicate including 12.5ul of FastStart Universal SYBR Green Master (Roche), 200nM primers, and 2.5ul of cDNA in a total volume of 25ul, qPCR protocol was using the recommended by Roche specification. The specificity of the DPB1 primers were confirmed by melt curve analysis using the dissociation step with single-peaked. All reactions were standardized to the reference gene GAPDH expression.

Linkage of HLA-DPB1 and SNPs

Genotype frequency was tested for Hardy–Weinberg equilibrium using Arlequin v 3.5.1.2. D’ was calculated as described by Paximzadis et al\[21\]. The maximum-likelihood (ML) method was used to estimate the LD, an Expectation-Maximization (EM) algorithm for multi-locus genotypic data were used by the observed data with an unknown gametic phase. ELB algorithm was used to estimate the gametic phase of the genotype data generated at all the polymorphic positions within the gene region when the recessive alleles are present. The statistical significance of the linkage disequilibrium between each of the allele pairs was evaluated by the approximate $X^2$ reported by previously\[19\]. All statistical significance was defined as $P<0.05$.

Meta-analysis study

In order to improve the influence of the HLA-DPB1 on the susceptible and spontaneous clearance of HBV infection, we performed a meta-analysis of them. Relevant studies were searched and identified by a computerized literature search of electronic databases, including Pubmed, EBSCO, Elsevier, and Web of Science, with English only as the language restriction.

The following index terms were used: ‘Hepatitis B’ and ‘HLA-DP’. The inclusion criteria were: (a) genotype frequencies of HLA-DPB1 can be obtained in healthy controls, HBV carriers, chronic HBV infections and HBV spontaneous clearance; (b) the study included specific criteria for enrolling the samples; (c) the study had a case–control design; and d) the numbers of cases and controls, and the alleles frequencies were clear stated. Studies that did not meet these criteria were excluded.

Statistics analysis
The Hardy–Weinberg equilibrium (HWE) of the genotype distributions and the linkage disequilibrium (LD) of the SNPs were examined using Arliquin 3.5 software, the differences for categorical variables and continuous variables were compared using the $\chi^2$ test and Student's t test, respectively. We used a logistic regression model to calculate the age- and gender-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) between the HLA-DPB1 variants and the risk of HBV infection. The meta-analysis was performed by Review Manager 5.2 software, the odd ratios (OR) with 95% confidence intervals (CI) were used to assess the strength of HLA-DPB1 polymorphisms in HBV susceptibility. Values of $P$ lower than 0.05 were considered statistically significant.

**Results**

**Relationship between HLA-DPB1 and rs9277535A/G in HBV infection**

The carriage of the HLA-DPB1 rs9277535A (0.52, 95%CI: 0.41–0.65) indicated a stronger protective factors with HBV infection, while rs9277535G (1.94, 95%CI: 1.54–2.46) was susceptible to HBV infection (Table 2).

|                | N   | AA     | AG      | GG      | A     | G     |
|----------------|-----|--------|---------|---------|-------|-------|
| **HBV group**  | 259 | 19 (7.3%) | 107 (41.3%) | 133 (51.4%) | 0.28  | 0.72  |
| **HC**         | 441 | 77 (17.5%) | 213 (48.3%) | 153 (34.7%) | 0.42  | 0.58  |
| **HBV versus HC** |    | AA versus GG + AG | GG + AG versus AA | A versus G | G versus A |
| $P$ value      |     | 0.001$^a$ | 0.001$^a$ | 0.001$^a$ | 0.001$^a$ |
| Risk ratio     |     | 0.37  | 1.99  | 0.52  | 1.94 |
| 95% CI         |     | (0.22–0.63) | (1.45–2.72) | (0.41–0.65) | (1.54–2.46) |

$^aP < 0.01$ (after Bonferroni correction), HBV: hepatitis B virus, HC: healthy control, CI: confidence interval.

HLA-DPB1 shows highly polymorphic, the most prevalence allele in our populations were HLA-DPB1*05:01, which (1.41, 95%CI: 1.14–1.76) was significantly associated with HBV susceptibility in Sichuan Han population. Both HLA-DPB1*04:02 (0.31, 95%CI: 0.16–0.59) were significantly associated with HBV protection in our study population (Table 3).
Table 3
Distribution of the HLA-DPB1 alleles in different groups.

| DPB1* | HC   | F(%) | HBV carriers | F(%) | P   | Risk ratio (HBV VS.HC) | 95% CI |
|-------|------|------|--------------|------|-----|------------------------|--------|
|       | N = 441 |    |               | N = 259 |     |                        |        |
| 01:01 | 8    | 0.9  | 2             | 0.4  | 0.22 | 0.42(0.09-2.00)         |        |
| 02:01 | 141  | 16.0 | 73            | 14.0 | 0.19 | 0.86(0.64–1.17)         |        |
| 02:02 | 62   | 7.0  | 30            | 5.8  | 0.22 | 0.81(0.52–1.28)         |        |
| 03:01 | 36   | 4.1  | 20            | 3.9  | 0.48 | 0.94(0.54–1.65)         |        |
| 04:01 | 67   | 7.6  | 31            | 6.0  | 0.15 | 0.77(0.50–1.20)         |        |
| 04:02 | 40   | 4.5  | 13            | 2.5  | 0.001² | 0.31(0.16–0.59)      |        |
| 04:03 | 1    | 0.1  | —             | —    | —   | —                      |        |
| 05:01 | 362  | 41.0 | 257           | 50   | 0.001² | 1.41(1.14–1.76)     |        |
| 09:01 | 5    | 0.6  | 5             | 1.0  | 0.29 | 1.71(0.49–5.93)         |        |
| 13:01 | 65   | 7.4  | 31            | 6.0  | 0.19 | 0.80(0.51–1.25)         |        |
| 14:01 | 24   | 2.7  | 12            | 2.3  | 0.39 | 0.85(0.42–1.71)         |        |
| 15:01 | 1    | 0.1  | 1             | 0.2  | —   | —                      |        |
| 16:01 | 1    | 0.1  | 1             | 0.2  | —   | —                      |        |
| 17:01 | 20   | 2.3  | 14            | 2.7  | 0.37 | 1.20 (0.60–2.39)        |        |
| 19:01 | 3    | 0.3  | 4             | 0.8  | 0.23 | 2.28(0.51–10.23)        |        |
| 21:01 | 28   | 3.2  | 21            | 4.1  | 0.24 | 1.29(0.72–2.29)         |        |
| 26:01 | 1    | 0.1  | —             | —    | —   | —                      |        |
| 28:01 | 6    | 0.7  | —             | —    | —   | —                      |        |
| 31:01 | 2    | 0.2  | —             | —    | —   | —                      |        |
| 35:01 | —    | —    | 1             | 0.2  | —   | —                      |        |
| 36:01 | 2    | 0.2  | 1             | 0.2  | —   | —                      |        |
| 38:01 | 3    | 0.3  | —             | —    | —   | —                      |        |

² P < 0.01 (after Bonferroni correction), HBV: hepatitis B virus, HC: healthy control, CI: confidence interval.
| DPB1* | F(%) | HBV carriers | F(%) | P | Risk ratio |
|-------|------|--------------|------|---|------------|
|       |      | (HBV VS.HC)  |      |   |            |
| 41:01 | 1    | 0.1          |      |   |            |
| 45:01 | 1    | 0.1          |      |   |            |
| 51:01 |      | 1            | 0.2  |   |            |
| 57:01 | 1    | 0.1          |      |   |            |
| 59:01 | 1    | 0.1          |      |   |            |

\(^aP \leq 0.01\) (after Bonferroni correction), HBV: hepatitis B virus, HC: healthy control, CI: confidence interval.

**Table 4**

Linkage disequilibrium between the HLA-DPB1 alleles and rs92777535 in different groups.

| HLA-DPB1 | Rs92777535 | F(%) | D’  | P   | Rs92777535 | F(%) | D’  | P   |
|----------|------------|------|-----|-----|------------|------|-----|-----|
| *02:01   | A          | 16.0 | 0.95| <0.001 | A          | 11.4 | 0.73| <0.001 |
| *02:02   | A          | 7.0  | 0.0 | <0.001 | A          | 4.4  | 0.68| <0.001 |
| *03:01   | G          | 4.1  | 1   | <0.001 | G          | 3.7  | 0.82| 0.02 |
| *04:01   | A          | 7.6  | 0.95| <0.001 | A          | 5.0  | 0.78| <0.001 |
| *04:02   | A          | 4.4  | 0.99| <0.001 | A          | 1.9  | 0.68| <0.001 |
| *05:01   | G          | 40.4 | 0.95| <0.001 | G          | 48.5 | 0.92| <0.001 |
| *13:01   | G          | 7.3  | 0.99| <0.001 | G          | 5.2  | 0.87| <0.001 |
| *14:01   | G          | 24   | 1   | <0.001 | G          | 2.1  | 0.78| NS  |
| *17:01   | A          | 2.3  | 1   | <0.001 | A          | 1.9  | 0.6 | <0.001 |
| *21:01   | G          | 3.1  | 0.99| <0.001 | G          | 4.1  | 1   | <0.001 |

HBV: hepatitis B virus, HC: healthy control.
Table 5
Characteristics of the studies regarding hepatitis B virus infection susceptibility.

| First author   | Year | Ethnicity | Total | Genotype method | Refs |
|----------------|------|-----------|-------|-----------------|------|
|                |      |           | Case  | Control         |      |
| Donaldson PT   | 2001 | Hong Kong | 121   | 123             | [5]  |
| Kamatani Y     | 2009 | Japanese  | 607   | 934             | [4]  |
| Nishida N      | 2014 | Japanese  | 488   | 464             | [11] |
| Nishida N      | 2014 | Korean    | 251   | 140             | [11] |
| Nishida N      | 2014 | Hong Kong | 280   | 156             | [11] |
| Nishida N      | 2014 | Thai      | 369   | 122             | [11] |
| Nishida N      | 2015 | Japanese  | 1357  | 1225            | [6]  |
| Nishida N      | 2016 | Japanese  | 2278  | 805             | [9]  |
| Zhu M          | 2016 | Chinese Han | 951   | 937             | [22] |
Table 6
Overall results regarding HLA-DPB1 polymorphisms in hepatitis B virus-susceptible patients.

| HLA-DPB1* | N  | Heterogeneity | Overall relationship |
|-----------|----|---------------|---------------------|
|           | i², % | P | Model | OR (95% CI) | P value |
| 02:01     | 9   | 14 | 0.32  | 0.73 (0.68–0.78) | < 0.00001 |
| 02:02     | 9   | 0  | 0.79  | 0.81 (0.71–0.93) | 0.002    |
| 03:01     | 9   | 23 | 0.24  | 1.05 (0.92–1.19) | 0.49     |
| 04:01     | 9   | 58 | 0.01  | 0.50 (0.40–0.63) | < 0.00001 |
| 04:02     | 8   | 61 | 0.01  | 0.49 (0.39–0.61) | < 0.00001 |
| 05:01     | 9   | 22 | 0.24  | 1.39 (1.32–1.47) | < 0.00001 |
| 09:01     | 9   | 58 | 0.01  | 1.55 (1.30–1.86) | < 0.00001 |
| 13:01     | 9   | 40 | 0.40  | 1.26 (1.08–1.47) | 0.003    |
| 14:01     | 9   | 0  | 0.67  | 0.97 (0.79–1.20) | 0.80     |
| 17:01     | 5   | 0  | 0.80  | 1.15 (0.88–1.51) | 0.31     |
Table 7
Meta-analysis of HLA-DPB1 polymorphisms and hepatitis B virus clearance.

| First author | Year | Ethnicity | Total | Genotype method | Refs |
|--------------|------|-----------|-------|-----------------|------|
|               |      |           | Case  | Control         |      |
| Cho SW       | 2008 | Koreans  | 80    | 384             | [7]  |
| Thomas R     | 2012 | Americans | 421  | 241             | [13] |
| Nishida N    | 2014 | Japanese | 570   | 488             | [11] |
| Nishida N    | 2014 | Korean   | 106   | 251             | [11] |
| Nishida N    | 2014 | Hong Kong | 84    | 280             | [11] |
| Nishida N    | 2014 | Thai     | 109   | 369             | [11] |
| Katrinli S   | 2017 | Turkey   | 85    | 94              | [8]  |

After meta-analysis, we found that the DPB1*02:01, DPB1*02:02, DPB1*04:01 and DPB1*04:02 were protective to HBV infection, however, DPB1*05:01, DPB1*09:01 and DPB1*13:01 associated with HBV susceptibility. DPB1*02:01, DPB1*04:01 and DPB1*04:02 were associated with HBV spontaneous clearance in Asian population, while DPB1*05:01 and DPB1*13:01 were associated with chronic HBV infection.

Table 8
Meta-analysis of HLA-DQB1 alleles associated with hepatitis B virus spontaneous clearance.

| HLA-DQB1* | N | Heterogeneity | Overall relationship |
|-----------|---|---------------|----------------------|
|           |   | $\chi^2$, % | $P$ | Model | OR (95% CI) | $P$ value |
| 02:01     | 6 | 10            | 0.35 | F     | 1.30 (1.15–1.46) | < 0.0001 |
| 02:02     | 5 | 6             | 0.37 | F     | 1.22 (0.94–1.59) | 0.14     |
| 03:01     | 6 | 36            | 0.23 | F     | 1.17 (0.91–1.52) | 0.23     |
| 04:01     | 7 | 62            | 0.01 | R     | 1.56 (1.16–2.11) | 0.004    |
| 04:02     | 6 | 78            | 0.0004 | R | 1.77 (0.98–3.02) | 0.06     |
| 05:01     | 5 | 75            | 0.003 | R   | 0.78 (0.66–0.92) | 0.004    |
| 09:01     | 5 | 59            | 0.04 | F     | 1.01 (0.58–1.77) | 0.97     |
| 13:01     | 6 | 35            | 0.16 | F     | 0.65 (0.51–0.84) | 0.0008   |
| 14:01     | 6 | 0             | 0.87 | F     | 0.68 (0.43–1.07) | 0.09     |
| 17:01     | 5 | 0             | 0.68 | F     | 1.28 (0.79–2.08) | 0.32     |
The expression of DPB1 mRNA levels in HBV infection

The HLA-DPB1 mRNA expression was significantly lower in the rs9277535AA genotype compared to the rs9277534GG genotype. The HLA-DPB1*05:01 and DPB1*21:01 in HBV group showed significantly lower HLA-DPB1 mRNA expression levels compared to the healthy control groups. As shown in table

The linkage disequilibrium between rs9277535A/G and HLA-DPB1 alleles

The LD test of HLA-DPB1 and rs9277535A/G indicated that the association between DPB1 alleles with different rs9277535A/G that make up the haplotypes. The HLA-DPB1*04:01 and 04:02 had strong linkage with rs9277535A, which play protective role in HBV infection, the HLA-DPB1*05:01 had strong linkage with rs9277535G, which susceptible to HBV infection.

Discussion

China is a relatively high endemic area of HBV infection, there are many HBV carriers, chronic hepatitis patients, cirrhosis and hepatocellular carcinoma patients caused by HBV infection, which cause heavy social burden[22]. After the introduction of the HBV vaccine into the immunization program in China in 1992, the government administered free HBV vaccine to newborns to reduce the spread of HBV. At the same time, China has adopted a variety of methods to prevent and control HBV, strengthen the standardized management of HBV screening and medical treatment for blood donors, and effectively control iatrogenic HBV infection. All the above measures have significantly reduced the infection rate of new HBV infections, and the total HBV prevalence rate in China has dropped to 5.49% by 2015[1]. Therefore, it is of great significance to study the infection mechanism of hepatitis B for the prevention and treatment of hepatitis B.

HLA-II genes play a key role in viral antigen presentation to mediate cellular and humoral immune responses. Since Kamatani and his colleagues[4] did GWAS in large HBV infection cohort shown that HLA-DPB1 and related single nucleotide polymorphism rs9277535A/G are a strongly risk factors for persistent infection with hepatitis B virus. Thereafter, many researches focused on and successfully repeated the association between HLA-DPB1 and HBV infection and infection outcomes. they found[11] that HLA-DPB1 *09:01 increased HBV susceptibility, DPB1*02:01 was not susceptible to HBV, and DPB1*02:01 was also associated with reduced risk of HBV progression to chronic HBV. Studies[13] in American populations also found that the allele with the greatest risk of infection for HBV was DPB1*01:01, and the allele with the greatest protection against HBV infection was DPB1*04:01. Subsequently, the genotypes of DPB1 * 05:01, 09:01, and DPB1 * 02:01, 04:01, and 04:02 were again found to be susceptible to HBV in Japanese[9] and Chinese[10] populations. The studies also found that some DPB1 alleles and rs9277535G related to weak HBV vaccines response[23], low sensitive of HBV drug
therapy\textsuperscript{[15]}, incidence of occult HBV infection\textsuperscript{[24]}, and also prone to hepatocellular carcinoma development\textsuperscript{[25]}. In our study, we found the strongly association between rs9277535 and HLA-DPB1 alleles and HBV infection susceptibility. We found the rs9277535A, HLA-DPB1*04:02 were protective factors for chronic HBV infection in this study population, the results were accordingly to previously. rs9277535G and HLA-DPB1*05:01 were significantly associated with HBV susceptibility in Sichuan Han population. Evidence reported here in suggests that HLA-DP have key role in HBV infection progression.

The influence of the HLA-DPB1 region on HBV recovery is due to levels of HLA-DPB1 expression and less likely to differences in the peptides presented by different HLA-DPB1 alleles. The HLA-DPB1 expression were significantly different rs9277535AA and rs9277535GG, the protect genotype 9277535AA has significantly lower HLA-DPB1 mRNA expression level compared than the risk genotype rs9277535GG in healthy controls, Thomas\textsuperscript{[13]} and his colleagues also demonstrated that rs9277534GG genotype, which confers susceptibility to HBV persistence with significantly higher levels of HLA-DP surface protein and transcript level expression in healthy donors, rs9277534GG have lower levels of HLA-DPB1 mRNA in HBV group, O'Brien\textsuperscript{[12]} had reported that rs9277535AA with higher HLA-DPB1 mRNA expression in liver associated with lower HBV odds ratios with chronic HBV, our study also get a similar result with HLA-DPB1 expression in PBMC. The HLA-DPB1*05:01 and DPB1*21:01 in HBV group showed significantly lower HLA-DPB1 mRNA expression levels compared to the healthy control groups. Previous research\textsuperscript{[7]} observed that decreased expression levels of DPA1 and DPB1 mRNA were correlated with the HBV activation after 2 years of treatment with HBV drugs, the high expression of DPA1 mRNA was associated with lower HBV viral load\textsuperscript{[21]}. These results suggesting that the persistence HBV infection may influenced by differences HLA-DPB1 expression, lower HLA-DPB1 expression may lower the function of antigen peptide present, at last, decrease the immune response to HBV viral, resulting HBV persistence infection risks.

Studies also found\textsuperscript{[10]} that amino acids at position 84–87 of the second exon antigen presentation sequence of DPB1 had a complete linkage with the DPB1 alleles, and there were two major amino acids at position 84–87 with GGPA and DENA, through bioinformatics analysis found that the four amino acids is located at the groove contacting peptide residues pocket-1, can be caused different antigen presenting functions, at last, caused different immunity function to HBV infection. Class II HLA molecules expression on the surface of antigen-presenting cells, to combine with antigenic peptide to CD4 + T helper cells. The T cell paly a crucial role in HBV response in host immune response.

Usually, HLA class II molecules present exogenous antigen peptide, However, HLA-DP molecules with beta-chains encoding DPGly84\textsuperscript{[26]} does not bind invariant chain (ii) via the class II-associated invariant chain peptide (CLIP) region to constitutively present endogenous peptides. And processed by the proteasome and transported to the ER by the transporter associated with antigen processing (TAP). Therefore, DP84Gly can uniquely uses both class I and II antigen processing pathways to present peptides derived from intracellular and extracellular sources, DP84Asp has not such endogenous antigen
presentation function. Therefore\textsuperscript{[27]}, this polymorphism has different functions in autoimmune, antiviral and tumor mechanisms through the different function of antigen presentation.

The DP84Gly genotype not only plays a unique antiviral function in adaptive immunity, but also as a ligand of NKp44\textsuperscript{[17]} to activate NKT cells to play an antiviral role in natural immune function. Compared with healthy controls, NK cells in CHB patients show inhibitory phenotypes, in which the expression of activated receptors NKp44 and NKp46 are down-regulated\textsuperscript{[28]}. Whether the DP84Gly genotype can promote the spontaneous clearance of HBV by binding NKp44 to activated NK after HBV infection has not been studied.

HLA-DPB1 expression associated with HBV infection was not verified in Chinese population, to the best of our knowledge, this is the first research to investigate the HLA-DPB1 mRNA expression in different HLA-DPB1 alleles and SNPs alleles, and the association between mRNA expression and HBV infection. Further research should be clearly to verified the role of NK cells and CD4 + T cells in DP84Gly including DPB1*04:01, DPB1*04:02, DPB1*02:01 and DPB1*02:02 in HBV protection and clearance.

**Conclusion**

HLA-DPB1 gene have a major effect on the risk of HBV infection, Rs9277535A, HLA-DPB1*02:01, DPB1*02:02, DPB1*04:01 and DPB1*04:02 protected against HBV infection, while Rs9277535G, HLA-DPB1*05:01, DPB1*09:01, and DPB1*13:01 prone to susceptible to HBV infection. HLA-DPB1*02:01 and DPB1*04:01 were prone to HBV spontaneous clearance, while HLA-DPB1*05:01 and DPB1*13:01 were associated with chronic HBV infection. Rs9277535GG have significantly higher HLA-DPB1 mRNA expression in HBV group compared that in HC group. Alleles with susceptible to HBV infection seems to decrease HLA-DPB1 mRNA expression.

**Abbreviations**

HBV: hepatitis B virus

HLA: human leukocyte antigens

APCs: antigen-presenting cells

CHB: chronic HBV carriers

HC: healthy controls

HBsAg: hepatitis B surface antigen

HBsAb: Hepatitis B surface antibody

HBeAg: Hepatitis Be antigen
HBeAb: Hepatitis Be antibody
HBcAb: Hepatitis core antibody
HCV: Hepatitis C virus
HIV: Human immunodeficiency virus
HWE: Hardy–Weinberg equilibrium

Declarations

Acknowledgments
The authors thank the participants for generously providing the venous blood samples.

Authors’ contributions
Ou GJ, Xu HX, and Ji X performed the experiments. Liu X collected and evaluated the samples. Ou GJ and Liu XJ wrote the original draft of the manuscript. Wang J and Liu XJ designed the experiments and performed the data analysis, discussed the results, and substantially revised the manuscript.

Competing interests
The authors declare that they have no competing interests.

Data availability
All the data and materials supporting the conclusions were included in the main paper.

Consent for publication
Not applicable.

Funding
This work was supported by the CAMS Innovation Fund for Medical Sciences under contract 2016-I2M-3-024, Funding of Sichuan Science and Technology Department under contract 2017RZ0047 and Ministry of Science and Technology of China, Grant/Award number: 2014EG150133. The CIFMS
program provided us blood samples and relevant data, funding of Sichuan Science and Technology Department project provide us the cytokine detect methods and methods of HLA-DPB1 typing, program of Ministry of Science and Technology of China provide us HBV relevant detect methods.

**Ethics approval and consent to participate**

This study was approved by the ethic committees of the Institution of Blood Transfusion, CAMS&PUMC, and was conducted according to the principles of the Declaration of Helsinki. All participants provided written informed consent before enrolment, and the study’s protocol was approved by the ethic committees of the Institution of Blood Transfusion, CAMS&PUMC.

**References**

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546–55.

2. Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):7–10.

3. Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden of liver disease: the major impact of China. Hepatology. 2014;60:2099–108.

4. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, Kubo M, Tsunoda T, Kamatani N, Kumada H, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009;41:591–5.

5. Donaldson PT, Ho S, Williams R, Johnson PJ. HLA class II alleles in Chinese patients with hepatocellular carcinoma. Liver. 2001;21:143–8.

6. Nishida N, Ohashi J, Sugiyama M, Tsuchiura T, Yamamoto K, Hino K, Honda M, Kaneko S, Yatsuhashi H, Koike K, et al. Effects of HLA-DPB1 genotypes on chronic hepatitis B infection in Japanese individuals. Tissue Antigens. 2015;86:406–12.

7. Cho SW, Cheong JY, Ju YS, Oh DH, Suh YJ, Lee KW. Human leukocyte antigen class II association with spontaneous recovery from hepatitis B virus infection in Koreans: analysis at the haplotype level. J Korean Med Sci. 2008;23:838–44.

8. Katrinli S, Nilay Karatas Erkut G, Ozdil K, Yilmaz Enc F, Ozturk O, Kahraman R, Tuncer I, Dinler Doganay G, Doganay L. HLA DPB1 15:01 Allele Predicts Spontaneous Hepatitis B Surface Antigen Seroconversion. Acta Gastroenterol Belg. 2017;80:351–5.

9. Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, Hino K, Honda M, Kaneko S, Yatsuhashi H, et al. Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. Sci Rep. 2016;6:24767.
10. Zhu M, Dai J, Wang C, Wang Y, Qin N, Ma H, Song C, Zhai X, Yang Y, Liu J, et al. Fine mapping the MHC region identified four independent variants modifying susceptibility to chronic hepatitis B in Han Chinese. Hum Mol Genet. 2016;25:1225–32.

11. Nishida N, Sawai H, Kashiwase K, Minami M, Sugiyama M, Seto WK, Yuen MF, Posuwan N, Poovorawan Y, Ahn SH, et al. New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. PLoS One. 2014;9:e86449.

12. O’Brien TR, Khoaar I, Pfeiffer RM, Maeder D, Yeager M, Schadt EE, Prokunina-Olsson L. Risk alleles for chronic hepatitis B are associated with decreased mRNA expression of HLA-DPA1 and HLA-DPB1 in normal human liver. Genes Immun. 2011;12:428–33.

13. Thomas R, Thio CL, Apps R, Qi Y, Gao X, Marti D, Stein JL, Soderberg KA, Moody MA, Goedert JJ, et al. A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol. 2012;86:6979–85.

14. Schone B, Bergmann S, Lang K, Wagner I, Schmidt AH, Petersdorf EW, Lange V. Predicting an HLA-DPB1 expression marker based on standard DPB1 genotyping: Linkage analysis of over 32,000 samples. Hum Immunol. 2018;79:20–7.

15. Matsuda H, Hiramatsu K, Akazawa Y, Nosaka T, Saito Y, Ozaki Y, Hayama R, Takahashi K, Naito T, Ofuji K, et al. Genetic polymorphism and decreased expression of HLA class II DP genes are associated with HBV reactivation in patients treated with immunomodulatory agents. J Med Virol. 2018;90:712–20.

16. Hiramatsu K, Matsuda H, Nemoto T, Nosaka T, Saito Y, Naito T, Takahashi K, Ofuji K, Ohtani M, Suto H, et al: Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C. J Med Virol 2017.

17. Niehrs A, Garcia-Beltran WF, Norman PJ, Watson GM, Holzemer A, Chapel A, Richert L, Pommerening-Roser A, Korner C, Ozawa M, et al. A subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44. Nat Immunol. 2019;20:1129–37.

18. Niehrs A, Altfeld M. Regulation of NK-Cell Function by HLA Class II. Front Cell Infect Microbiol. 2020;10:55.

19. Ou G, Liu X, Yang L, Yu H, Ji X, Liu F, Xu H, Qian L, Wang J, Liu Z. Relationship between HLA-DPA1 mRNA expression and susceptibility to hepatitis B. J Viral Hepat. 2019;26:155–61.

20. Ou G, Xu H, Yu H, Liu X, Yang L, Ji X, Wang J, Liu Z. The roles of HLA-DQB1 gene polymorphisms in hepatitis B virus infection. J Transl Med. 2018;16:362.

21. Paximadis M, Mathebula TY, Gentle NL, Vardas E, Colvin M, Gray CM, Tiemessen CT, Puren A. Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population. Hum Immunol. 2012;73:80–92.

22. Shin HR, Oh JK, Masuyer E, Curado MP, Bouvard V, Fang YY, Wiangnon S, Sripa B, Hong ST. Epidemiology of cholangiocarcinoma: an update focusing on risk factors. Cancer Sci. 2010;101:579–85.
23. Wang LY, Chen CF, Wu TW, Lai SK, Chu CC, Lin HH. Response to hepatitis B vaccination is co-determined by HLA-DPA1 and -DPB1. Vaccine. 2019;37:6435–40.

24. Mardian Y, Yano Y, Wasityastuti W, Ratnasari N, Liang Y, Putri WA, Triyono T, Hayashi Y. Genetic polymorphisms of HLA-DP and isolated anti-HBc are important subsets of occult hepatitis B infection in Indonesian blood donors: a case-control study. Virol J. 2017;14:201.

25. Zhang Q, Yin J, Zhang Y, Deng Y, Ji X, Du Y, Pu R, Han Y, Zhao J, Han X, et al. HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol. 2013;87:12176–86.

26. Yamashita Y, Anczurowski M, Nakatsugawa M, Tanaka M, Kagoya Y, Sinha A, Chamoto K, Ochi T, Guo T, Saso K, et al. HLA-DP(84Gly) constitutively presents endogenous peptides generated by the class I antigen processing pathway. Nat Commun. 2017;8:15244.

27. Anczurowski M, Hirano N. Mechanisms of HLA-DP Antigen Processing and Presentation Revisited. Trends Immunol. 2018;39:960–4.

28. Li X, Zhou L, Gu L, Gu Y, Chen L, Lian Y, Huang Y. Veritable antiviral capacity of natural killer cells in chronic HBV infection: an argument for an earlier anti-virus treatment. J Transl Med. 2017;15:220.

Figures
Figure 1

HLA-DPB1 mRNA expression in rs9277535 alleles
Figure 2

HLA-DPB1 mRNA expression levels of rs9277535 alleles in the hepatitis B virus-infected (HBV) and healthy control (HC) groups.
Figure 3

HLA-DPB1 mRNA expression levels in the hepatitis B virus-infected (HBV) and healthy control (HC) groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supfiguresandtables.docx
